These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32003684)

  • 41. The structure and function of the glucagon-like peptide-1 receptor and its ligands.
    Donnelly D
    Br J Pharmacol; 2012 May; 166(1):27-41. PubMed ID: 21950636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the glucagon receptor family for diabetes and obesity therapy.
    Cho YM; Merchant CE; Kieffer TJ
    Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.
    Yang DH; Zhou CH; Liu Q; Wang MW
    Acta Pharmacol Sin; 2015 Sep; 36(9):1033-42. PubMed ID: 26279155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.
    Unger J
    Curr Diab Rep; 2013 Oct; 13(5):663-8. PubMed ID: 23955813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R; Almutairi M; Ussher JR
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glucagon-like peptide-1 and control of insulin secretion.
    Thorens B
    Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
    Rotella CM; Pala L; Mannucci E
    J Endocrinol Invest; 2005 Sep; 28(8):746-58. PubMed ID: 16277173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
    Gromada J; Brock B; Schmitz O; Rorsman P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucagon and glucagon-like peptide receptors as drug targets.
    Estall JL; Drucker DJ
    Curr Pharm Des; 2006; 12(14):1731-50. PubMed ID: 16712485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
    De León DD; Crutchlow MF; Ham JY; Stoffers DA
    Int J Biochem Cell Biol; 2006; 38(5-6):845-59. PubMed ID: 16202636
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
    Drucker DJ
    Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
    Drucker DJ
    Cell Metab; 2018 Apr; 27(4):740-756. PubMed ID: 29617641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gut hormone polyagonists for the treatment of type 2 diabetes.
    Brandt SJ; Götz A; Tschöp MH; Müller TD
    Peptides; 2018 Feb; 100():190-201. PubMed ID: 29412819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.